CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tessler, M.
Right arrow Articles by Mendelson, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tessler, M.
Right arrow Articles by Mendelson, J.

Canadian Journal of Anesthesia, Vol 39, 509-511, Copyright © 1992 by Canadian Anesthesiologists' Society

ARTICLES

Growth curves of Staphylococcus aureus, Candida albicans, and Moraxella osloensis in propofol and other media

M Tessler, A Dascal, S Gioseffini, M Miller and J Mendelson
Department of Anaesthesia and Medicine, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada.

Propofol, 2,6 diisopropylphenol, in an emulsion formulation (Diprivan), has been associated with postsurgical infections caused by Staphylococcus aureus, Moraxella osloensis and Candida albicans. These organisms were individually inoculated into each of the following media: (1) the emulsion preparation of propofol, (2) Intralipid 10%, (3) pure 2,6 diisopropylphenol, and (4) trypticase soy broth (TSB). The organisms were incubated and subcultured hourly for eight hours at room temperature. Propofol supported the growth of all three organisms, but for S. aureus and M. osloenis, the growth rate was slower in propofol than in TSB (P less than 0.05). There was no difference between the growth rate of any organism in propofol than in Intralipid 10%. The authors conclude that propofol, in the emulsion formulation, supports bacterial growth and, therefore, must be prepared for administration in an aseptic manner. Also, by administering propofol soon after preparation, the risk of introduction of a significant inoculum to the patient will be reduced.


This article has been cited by other articles:


Home page
 Canadian J. AnesthesiaHome page
I. H. Lorenz, C. Kolbitsch, C. Lass-Florl, I. Gritznig, B. Vollert, W. Lingnau, P. L Moser, and A. Benzer
Routine handling of propofol prevents contamination as effectively as does strict adherence to the manufacturer's recommendations: [Le maniement d'usage du propofol previent la contamination aussi effectivement que la stricte adhesion aux recommandations du fabricant]
Can J Anesth, April 1, 2002; 49(4): 347 - 352.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. I. Vidovich, L. R. Peterson, and H. Y. Wong
The Effect of Lidocaine on Bacterial Growth in Propofol
Anesth. Analg., April 1, 1999; 88(4): 936 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
I. Wachowski, D. T. Jolly, J. Hrazdil, J. C. Galbraith, M. Greacen, and A. S. Clanachan
The Growth of Microorganisms in Propofol and Mixtures of Propofol and Lidocaine
Anesth. Analg., January 1, 1999; 88(1): 209 - 212.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. N. Bennett, M. M. McNeil, L. A. Bland, M. J. Arduino, M. E. Villarino, D. M. Perrotta, D. R. Burwen, S. F. Welbel, D. A. Pegues, L. Stroud, et al.
Postoperative Infections Traced to Contamination of an Intravenous Anesthetic, Propofol
N. Engl. J. Med., July 20, 1995; 333(3): 147 - 154.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the Canadian Anesthesiologists' Society.